Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
we decrease » _ decrease (Expand Search), teer decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 8,941 - 8,960 results of 34,550 for search '(( 50 ((nn decrease) OR (a decrease)) ) OR ( 100 ((we decrease) OR (mean decrease)) ))', query time: 0.86s Refine Results
  1. 8941
    Table_3_Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngeal carcinoma.xlsx

    Table_3_Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngea... by Siqi Tang (3998222)

    Published 2023
    “…The KIF18B high expression group exhibited a higher TIDE score and elevated IC50 values for the commonly used chemotherapy drugs, gemcitabine, oxaliplatin, and 5-fluorouracil.…”
    Save to List
    Saved in:
  2. 8942
    Table_1_Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngeal carcinoma.xlsx

    Table_1_Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngea... by Siqi Tang (3998222)

    Published 2023
    “…The KIF18B high expression group exhibited a higher TIDE score and elevated IC50 values for the commonly used chemotherapy drugs, gemcitabine, oxaliplatin, and 5-fluorouracil.…”
    Save to List
    Saved in:
  3. 8943
    Table_2_Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngeal carcinoma.xlsx

    Table_2_Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngea... by Siqi Tang (3998222)

    Published 2023
    “…The KIF18B high expression group exhibited a higher TIDE score and elevated IC50 values for the commonly used chemotherapy drugs, gemcitabine, oxaliplatin, and 5-fluorouracil.…”
    Save to List
    Saved in:
  4. 8944
    Impingement area at the anteroinferior femoral neck in relation to different femoral versions and degrees of hip flexion.

    Impingement area at the anteroinferior femoral neck in relation to different femoral versions and degrees of hip flexion. by Jonathan Bourget-Murray (10884942)

    Published 2021
    Save to List
    Saved in:
  5. 8945
    DataSheet_2_IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia.docx

    DataSheet_2_IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia.docx by Joaquin Garcia-Solorio (18296686)

    Published 2024
    “…A decrease in OS was found in IKZF1<sup>MUT</sup> and CDKN2A/2B<sup>MUT</sup> patients, but the significance was lost after IKZF1<sup>plus</sup> was removed.…”
    Save to List
    Saved in:
  6. 8946
    DataSheet_1_IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia.xlsx

    DataSheet_1_IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia.xlsx by Joaquin Garcia-Solorio (18296686)

    Published 2024
    “…A decrease in OS was found in IKZF1<sup>MUT</sup> and CDKN2A/2B<sup>MUT</sup> patients, but the significance was lost after IKZF1<sup>plus</sup> was removed.…”
    Save to List
    Saved in:
  7. 8947
    Liver injury analysis.

    Liver injury analysis. by Véronique Cheff (14559285)

    Published 2023
    Save to List
    Saved in:
  8. 8948
    Cyclic fatigue test block.

    Cyclic fatigue test block. by Beliz Özel (16475132)

    Published 2024
    Save to List
    Saved in:
  9. 8949
    Initial RBC dominant clot compaction in the <i>in vitro</i> MCA model without and with collateral with alteplase applied at clinically relevant concentration (1.3 mg L<sup>-1</sup>).

    Initial RBC dominant clot compaction in the <i>in vitro</i> MCA model without and with collateral with alteplase applied at clinically relevant concentration (1.3 mg L<sup>-1</sup>... by Sandra Thalerová (11434762)

    Published 2024
    Save to List
    Saved in:
  10. 8950
    GFP localization and expression in wild-type and <i>tbc-2</i> mutants.

    GFP localization and expression in wild-type and <i>tbc-2</i> mutants. by İçten Meraş (13184380)

    Published 2022
    Save to List
    Saved in:
  11. 8951
    Standardized differences between the unweighted SCAPIS participants and weighted SCAPIS participants standardized to match the target population on individual and neighborhood-level sociodemographic characteristics.

    Standardized differences between the unweighted SCAPIS participants and weighted SCAPIS participants standardized to match the target population on individual and neighborhood-leve... by Carl Bonander (5563244)

    Published 2022
    Save to List
    Saved in:
  12. 8952
    Binding of nucleotide and compound 1 to yeast F<sub>1</sub> α- and β-subunits.

    Binding of nucleotide and compound 1 to yeast F<sub>1</sub> α- and β-subunits. by Lindsay B. Tulloch (1266861)

    Published 2017
    Save to List
    Saved in:
  13. 8953
    B-THP-Ts bind to C-terminal GFP-PTP tagged F<sub>1</sub> α- and β- subunits.

    B-THP-Ts bind to C-terminal GFP-PTP tagged F<sub>1</sub> α- and β- subunits. by Lindsay B. Tulloch (1266861)

    Published 2017
    Save to List
    Saved in:
  14. 8954
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Save to List
    Saved in:
  15. 8955
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Save to List
    Saved in:
  16. 8956
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Save to List
    Saved in:
  17. 8957
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Save to List
    Saved in:
  18. 8958
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Save to List
    Saved in:
  19. 8959
    Effects of compounds on mitochondrial membrane potential.

    Effects of compounds on mitochondrial membrane potential. by Lindsay B. Tulloch (1266861)

    Published 2017
    Save to List
    Saved in:
  20. 8960
    Inhibition of ATP production in digitonin-permeabilsed cells.

    Inhibition of ATP production in digitonin-permeabilsed cells. by Lindsay B. Tulloch (1266861)

    Published 2017
    Save to List
    Saved in:

Search Tools: